Technical Analysis for YMAB - Y-mAbs Therapeutics, Inc.
|Grade||Last Price||% Change||Price Change|
YMAB closed down 4.44 percent on Monday, December 17, 2018, on 61 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.
|Weak or Absent||N/A||Down||Down|
|See historical YMAB trend table...|
|Date||Alert Name||Type||% Chg|
|Dec 17||Lower Bollinger Band Walk||Weakness||0.00%|
|Dec 17||Wide Bands||Range Expansion||0.00%|
|Dec 17||Down 3 Days in a Row||Weakness||0.00%|
|Dec 17||Lower Bollinger Band Touch||Weakness||0.00%|
|Dec 17||Oversold Stochastic||Weakness||0.00%|
|Dec 14||Lower Bollinger Band Walk||Weakness||-4.44%|
|Dec 14||Inside Day||Range Contraction||-4.44%|
|Dec 14||Lower Bollinger Band Touch||Weakness||-4.44%|
|Dec 14||Oversold Stochastic||Weakness||-4.44%|
|Dec 13||Doji - Bullish?||Reversal||-5.14%|
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicatorsBasic chart:
- Earnings date: ???
Y-mAbs Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody therapeutic products for cancer treatment in the United States. It is developing naxitamab for the treatment of pediatric patients with relapsed or refractory, high-risk neuroblastoma, as well as other GD2 positive tumors; and omburtamab for the treatment of pediatric patients with central nervous system/leptomeningeal metastases, desmoplastic small round cell tumors, diffuse intrinsic pontine glioma, and other B7-H3 positive tumors. The company has a license and research collaboration agreement with Memorial Sloan-Kettering Cancer Center. Y-mAbs Therapeutics, Inc. was founded in 2015 and is headquartered in New York, New York.
|Indicator||Bull Case||Neutral / Hold||Bear Case|
|Oversold / Overbought|
|Summary:||Counts: 0 bullish, 1 bearish and 4 neutral indicators. You may wish to incorporate that into your trading strategies.|
See more YMAB news...
|52 Week High||31.0|
|52 Week Low||18.0|
|200-Day Moving Average||0.0|
|50-Day Moving Average||23.5818|
|20-Day Moving Average||23.8505|
|10-Day Moving Average||22.494|
|Average True Range||2.1979|
|Chandelier Exit (Long, 3 ATRs )||20.9913|
|Chandelier Exit (Short, 3 ATRs )||26.5937|
|Upper Bollinger Band||27.4526|
|Lower Bollinger Band||20.2484|
|Percent B (%b)||0.03|
|MACD Signal Line||-0.4501|
|Pivot Point Level||Traditional / Classic||Fibonacci||Demark||Woodie||Camarilla|
|Resistance 4 (R4)||23.44|
|Resistance 3 (R3)||23.61||22.80||22.95|
|Resistance 2 (R2)||22.80||22.04||22.71||22.78|
|Resistance 1 (R1)||21.63||21.57||21.23||21.46||22.61|
|Support 1 (S1)||19.65||20.06||19.25||19.48||18.33|
|Support 2 (S2)||18.84||19.59||18.75||18.16|
|Support 3 (S3)||17.67||18.84||18.00|
|Support 4 (S4)||17.50|